Fig. 3From: B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patientsTarget-to-background ratios of positron emission tomography (PET)-positive joints in relation to clinical response, in those patients who had at least one PET-positive joint on visual interpretationBack to article page